New hope for lymphoma patients when CAR-T fails: tailored drug cocktail shows promise
NCT ID NCT07602322
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a personalized treatment approach for people with large B-cell lymphoma whose cancer did not respond to CAR-T cell therapy. Researchers will analyze the tumor's surrounding environment to classify it into one of four subtypes, then give patients a drug combination tailored to that subtype. The goal is to see if this customized strategy helps patients live longer without their cancer progressing compared to a standard single drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Glofitamab combined with other drugs (BCL-2 inhibitor, PD-1 inhibitor, lenalidomide, radiotherapy, BTK inhibitor, or HDAC inhibitor) based on tumor subtype
What this could lead to
If successful, this could offer a more effective treatment option for patients with large B-cell lymphoma who have not responded to CAR-T therapy, potentially extending the time they live without their disease worsening.
What could go wrong
This is a small, early-phase trial with only 60 participants, so results may not apply to all patients. The personalized approach is new and may not work better than standard therapy, and combination drugs can have significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai,
Shanghai, Shanghai Municipality, 200020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••